← ANALYST RATINGS · TIPRANKS
Ligand Pharma (LGND): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $360, the highest $397, the lowest $326. The average is +21.8% from the last price of $296.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $345 | Buy | +16.7% | Initiated | 25.09.26on TipRanks 04:45 | +0.3%next day +4.9% · 5 days +0.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $331 → $340+2.7% | Buy | +15.0% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $328 → $340+3.7% | Buy | +15.0% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $321 → $336+4.7% | Buy | +13.7% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $315 → $325+3.2% | Hold | +10.0% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $329 → $349+6.1% | Buy | +18.1% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $329 → $342+4.0% | Buy | +15.7% | Reiterated | 24.09.26on TipRanks 17:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $358 | Buy | +21.1% | Reiterated | 24.09.26on TipRanks 11:15 | +0.3%next day +0.3% · 5 days +1.7% | ↗ |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Assigned | 24.09.26on TipRanks Sep 23 04:10 | +0.7%next day +0.3% · 5 days +5.4% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $390 → $397+1.8% | Buy | +34.3% | Reiterated | 23.09.26on TipRanks 05:50 | +0.7%next day +0.3% · 5 days +5.4% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | — | Buy | — | Reiterated | 22.09.26on TipRanks Sep 23 06:05 | +2.9%next day +0.7% · 5 days +5.2% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $388 | Buy | +31.3% | Reiterated | 22.09.26on TipRanks Sep 23 04:45 | +2.9%next day +0.7% · 5 days +5.2% | ↗ |
| Douglas Miehm★★★★★★★★★★#2559 · hits 51% · avg +5.3% | RBC Capital | $345 | Buy | +16.7% | Reiterated | 09.08.26on TipRanks Aug 10 07:25 | +0.9%next day −2.0% · 5 days −1.3% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $326 | Buy | +10.3% | Reiterated | 07.08.26on TipRanks 08:45 | −2.9%next day +0.9% · 5 days +0.1% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | $275 → $335+21.8% | Buy | +13.4% | Reiterated | 16.07.26on TipRanks 08:05 | +0.6%next day +3.3% · 5 days +3.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Ligand Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $356 at a price of $312 (+14.1%); now: $360 at $296 (+21.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 20 | 19 | 16 | 20 | 24 | 16 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.31 (from $1.93 to $2.49). Last quarter: $2.37.
Sales
Next quarter’s sales estimate — $78M (from $65M to $92M). Last quarter: $64M.
Best top-analyst consensus in the sector · Healthcare
About Ligand Pharma
- CEO: Todd C. Davis
- Employees: 47
- 555 Heritage Drive, Jupiter, FL, 33458, US
- www.ligand.com
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is h
Data from the stock’s TipRanks forecast page, read 120 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗